We are live on ! Find out more
FAM

Fred Alger Management Portfolio holdings

AUM $22.8B
1-Year Est. Return 64.63%
This Fund
S&P 500
This Quarter Est. Return
+6.58%
1 Year Est. Return
+64.63%
3 Year Est. Return
+243.99%
5 Year Est. Return
+318.3%
10 Year Est. Return
+1,899.64%
AUM
$20.3B
AUM Growth
+$134M
Cap. Flow
-$851M
Cap. Flow %
-4.19%
Top 10 Hldgs %
20.94%
Holding
692
New
87
Increased
159
Reduced
292
Closed
68

Sector Composition

Rank Sector Weight
1 Healthcare 17.85%
2 Technology 16.42%
3 Consumer Discretionary 13.2%
4 Industrials 11.28%
5 Financials 11.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CRM icon
26
Salesforce
CRM
$134B
$200M 0.99%
3,450,339
+343,022
+11% +$18.5M
DHR icon
27
Danaher
DHR
$135B
$197M 0.97%
3,727,025
+1,463,876
+65% +$75.2M
BFH icon
28
Bread Financial
BFH
$4.21B
$195M 0.96%
867,274
+483,080
+126% +$98.4M
COV
29
DELISTED
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
$192M 0.94%
2,127,111
+27,185
+1% +$2.03M
APC
30
DELISTED
Anadarko Petroleum
APC
$189M 0.93%
1,728,892
+323,446
+23% +$32.9M
MU icon
31
Micron Technology
MU
$1.04T
$186M 0.92%
5,654,110
+1,431,481
+34% +$39M
JCI icon
32
Johnson Controls International
JCI
$87.5B
$185M 0.91%
3,536,757
-475,126
-12% -$23.6M
DVN icon
33
Devon Energy
DVN
$51.9B
$178M 0.88%
+2,241,580
New +$163M
MSFT icon
34
Microsoft
MSFT
$2.84T
$176M 0.87%
4,219,918
+2,022,737
+92% +$81.9M
CELG
35
DELISTED
Celgene Corp
CELG
$175M 0.86%
2,037,530
+2,037,364
+1,227,328% +$155M
STJ
36
DELISTED
St Jude Medical
STJ
$174M 0.86%
2,511,322
+636,748
+34% +$41.3M
PCP
37
DELISTED
PRECISION CASTPARTS CORP
PCP
$163M 0.8%
646,534
+282,578
+78% +$72.2M
BX icon
38
Blackstone
BX
$104B
$159M 0.78%
4,840,927
+963,919
+25% +$29.7M
BIIB icon
39
Biogen
BIIB
$29.9B
$149M 0.74%
473,599
-34,220
-7% -$10.3M
PCYC
40
DELISTED
PHARMACYCLICS INC
PCYC
$133M 0.65%
1,477,603
+12,800
+0.9% +$1.2M
NOV icon
41
NOV
NOV
$7.45B
$131M 0.64%
1,590,188
+137,398
+9% +$10.2M
ABBV icon
42
AbbVie
ABBV
$458B
$126M 0.62%
2,231,158
-10,793
-0.5% -$566K
CSGP icon
43
CoStar Group
CSGP
$11.3B
$123M 0.6%
7,762,040
+6,476,000
+504% +$105M
PARA
44
DELISTED
Paramount Global Class B
PARA
$122M 0.6%
1,963,261
-692,142
-26% -$41.2M
HAL icon
45
Halliburton
HAL
$27.9B
$120M 0.59%
1,689,607
+52,370
+3% +$3.36M
TWC
46
DELISTED
TIME WARNER CABLE INC NEW COM STK
TWC
$120M 0.59%
814,445
+200,729
+33% +$28.2M
AIG icon
47
American International
AIG
$41.9B
$120M 0.59%
2,197,662
+1,563,987
+247% +$82.8M
LRCX icon
48
Lam Research
LRCX
$382B
$117M 0.58%
17,312,230
-2,997,740
-15% -$17.9M
JPM icon
49
JPMorgan Chase
JPM
$939B
$116M 0.57%
2,016,243
-1,126,743
-36% -$63.3M
RL icon
50
Ralph Lauren
RL
$22.2B
$115M 0.56%
713,659
+211,436
+42% +$32.6M

Similar funds

Fred Alger Management's Q2 2014 Portfolio in Review

As of Q2 2014, Fred Alger Management held 692 positions worth $20.3B, up 0.66% from $20.2B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Fred Alger Management withdrew a net $851M in Q2 2014, closing 68 positions and reducing 292 holdings. Its most notable exit was Charles River Laboratories, an estimated $55.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Fred Alger Management opened a new position in Devon Energy worth $178M.

  • Fred Alger Management's largest Q2 2014 buy was Devon Energy: 2,241,580 shares worth $178M.
  • Fred Alger Management added most to Celgene Corp in Q2 2014, an estimated $155M increase.
  • Fred Alger Management's biggest Q2 2014 reduction was Coterra Energy, cutting an estimated $147M.
  • Fred Alger Management fully exited Charles River Laboratories in Q2 2014, selling an estimated $55.5M.
  • Fred Alger Management's ten largest holdings make up 21% of its $20.3B portfolio in Q2 2014.
  • Fred Alger Management opened 87 new positions and closed 68 in Q2 2014.
  • Fred Alger Management's portfolio value rose 0.66% quarter-over-quarter to $20.3B.

Based on Fred Alger Management's 13F filing for Q2 2014, filed 14 Aug 2014.